Welcome to our dedicated page for Scopus Biopharma news (Ticker: SCPS), a resource for investors and traders seeking the latest updates and insights on Scopus Biopharma stock.
Scopus Biopharma Inc. (SCPS) is an innovative biopharmaceutical company developing cutting-edge therapies for diseases with critical unmet needs. This dedicated news hub provides investors and industry professionals with essential updates on clinical trials, strategic partnerships, and therapeutic advancements.
Access timely information about SCPS's progress in immuno-oncology treatments, antiviral therapies, and regenerative medicine development. Our curated news collection features verified updates on trial milestones, research collaborations with leading institutions, and financial developments impacting the company's trajectory.
Key updates include progress reports on cancer treatment candidates, partnership announcements with academic research centers, and analyses of the company's financial position. Bookmark this page to stay informed about SCPS's contributions to biopharmaceutical innovation and their pursuit of transformative medical solutions.
Scopus BioPharma (Nasdaq: SCPS) announced the presentation of key scientific data at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 8-12, 2022, in Boston, Massachusetts. The company, dedicated to developing transformational therapeutics for unmet medical needs, operates through its immuno-oncology subsidiary, Duet BioTherapeutics. Launched in September 2021, Duet focuses on innovative immunotherapy assets, including three CpG-STAT3 inhibitors. The press release also includes a disclaimer regarding forward-looking statements and associated risks.
Scopus BioPharma (Nasdaq: SCPS) announced the completion of recapitalization transactions aimed at enhancing shareholder value. This includes eliminating warrants for approximately 21 million shares and valuing its subsidiary, Duet BioTherapeutics, at $25 million, which Scopus owns about 90%. The recapitalization is expected to act as a catalyst for increasing Scopus' stock price. Duet is positioned to raise capital and go public in 2023, significantly advancing its proprietary antisense technology and research initiatives.
Scopus BioPharma Inc. (Nasdaq: SCPS) has appointed Raphael Hofstein, Ph.D. to its Board of Directors, bringing extensive experience in biotechnology. Hofstein has co-founded over 60 biopharma companies and is currently Chairman of Fibrocor Therapeutics. His insights are expected to enhance the company's Duet Platform, which targets the challenging protein STAT3, utilizing innovative nucleic acid-based molecules. This appointment follows recent board changes due to a contested election. Investors remain cautious due to ongoing legal challenges regarding the election results.
Scopus BioPharma (Nasdaq: SCPS) announced that Dr. Alan Horsager, CEO of Duet BioTherapeutics, will present at the 3rd Annual STING & TLR-Targeting Therapies Summit from March 22-24, 2022. His presentation titled TLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology will focus on novel methods of targeting immune pathways. The Duet Platform, launched in September 2021, integrates immunotherapy assets and includes three distinct CpG-STAT3 inhibitors: DUET-01, DUET-02, and DUET-03. These inhibitors aim to enhance immune responses against tumors.
Scopus BioPharma Inc. (Nasdaq: SCPS) announced the results of its Annual Meeting, revealing that over 90% of shares voted by unaffiliated stockholders supported the re-election of directors. However, the voting results are being challenged in court by directors against Morris C. Laster, who claims to own 6,000,000 shares. Legal actions may impact the ultimate outcome of the meeting.
The company emphasizes its commitment to protect legitimate shareholder interests against potential misconduct by the Lasters. Scopus is focused on developing innovative therapies for serious diseases.
On January 6, 2022, Dr. Morris C. Laster announced the successful election of his nominees, Mordechai Saar Hacham and Joshua Levine, to the Board of Directors of Scopus BioPharma (Nasdaq: SCPS). The announcement followed the Company's 2021 Annual Meeting, where Hacham and Levine received 8,276,505 and 8,276,338 votes, respectively, defeating the incumbent nominees. Additionally, stockholders voted against the ratification of Citrin Cooperman & Company as the Company's independent accounting firm. Dr. Laster emphasized that this outcome reflects stockholder desires for more independent stewardship.
Scopus BioPharma (Nasdaq: SCPS) has issued a second letter to stockholders ahead of its Annual Meeting on December 20, urging them to vote “FOR ALL” director nominees on the WHITE proxy card. The company highlights concerns about Morris C. Laster’s ongoing campaign for board control, which it claims has destroyed over $100 million in shareholder value this year. The stock price has fallen from $10 to below $2, despite the company's advancements in regulatory milestones and asset acquisition. Scopus asserts that Laster's motives are self-serving and calls for unity among shareholders.
Scopus BioPharma Inc. (Nasdaq: SCPS) is urging stockholders to support its director nominees, Dr. Raphael Hofstein and Dr. David S. Battleman, in the upcoming reconvened Annual Meeting on December 20, 2021. The company has raised $9.75 million in non-dilutive financing, fully absorbed by its Executive Committee's contribution of warrants to purchase six million shares. Scopus emphasizes its commitment to developing transformational therapeutics for cancer treatment, leveraging groundbreaking scientific advances and achieving key developmental milestones between now and early 2023.
